Literature DB >> 19725582

Design and synthesis of androgen receptor antagonists with bulky side chains for overcoming antiandrogen resistance.

Jinming Zhou1, Guoyan Geng, Qingwen Shi, Francoise Sauriol, Jian Hui Wu.   

Abstract

Incorporation of curcumin and beta-ionone into one chemical entity led to identification of a novel antiandrogen with two bulky side chains, 6, which is a pure antagonist of the wild-type and the T877A, W741C, and H874Y mutated androgen receptors (AR), showing no cross-reactivity with progesterone receptor and low micromolar cytotoxicity in LNCaP, PCa-2b, 22Rv1, and C4-2B prostate cancer cells. Molecular modeling indicates 6 adopts a "Y"-shape conformation and forms multiple hydrogen bonds with AR backbone.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19725582     DOI: 10.1021/jm801218k

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  17 in total

1.  Design and Synthesis of 4-(4-Benzoylaminophenoxy)phenol Derivatives As Androgen Receptor Antagonists.

Authors:  Ayumi Yamada; Shinya Fujii; Shuichi Mori; Hiroyuki Kagechika
Journal:  ACS Med Chem Lett       Date:  2013-08-19       Impact factor: 4.345

2.  Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy.

Authors:  Hifzur Rahman Siddique; Shrawan Kumar Mishra; R Jeffery Karnes; Mohammad Saleem
Journal:  Clin Cancer Res       Date:  2011-06-28       Impact factor: 12.531

3.  The curcumin analog ca27 down-regulates androgen receptor through an oxidative stress mediated mechanism in human prostate cancer cells.

Authors:  Alexandra M Fajardo; Debra A MacKenzie; Ming Ji; Lorraine M Deck; David L Vander Jagt; Todd A Thompson; Marco Bisoffi
Journal:  Prostate       Date:  2011-07-27       Impact factor: 4.104

Review 4.  Androgen receptor variation affects prostate cancer progression and drug resistance.

Authors:  Edel McCrea; Tristan M Sissung; Douglas K Price; Cindy H Chau; William D Figg
Journal:  Pharmacol Res       Date:  2016-10-07       Impact factor: 7.658

5.  Synthesis and in vitro characterization of ionone-based compounds as dual inhibitors of the androgen receptor and NF-κB.

Authors:  Weiguo Liu; Jinming Zhou; Guoyan Geng; Rongtuan Lin; Jian Hui Wu
Journal:  Invest New Drugs       Date:  2013-10-23       Impact factor: 3.850

Review 6.  Perspectives on new synthetic curcumin analogs and their potential anticancer properties.

Authors:  Alok Vyas; Prasad Dandawate; Subhash Padhye; Aamir Ahmad; Fazlul Sarkar
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

7.  Pyridine analogues of curcumin exhibit high activity for inhibiting CWR-22Rv1 human prostate cancer cell growth and androgen receptor activation.

Authors:  Dai-Ying Zhou; Su-Qing Zhao; Zhi-Yun DU; X I Zheng; Kun Zhang
Journal:  Oncol Lett       Date:  2016-05-06       Impact factor: 2.967

8.  Potential applications of curcumin and its novel synthetic analogs and nanotechnology-based formulations in cancer prevention and therapy.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Chin Med       Date:  2011-08-23       Impact factor: 5.455

9.  Resistance to cancer treatment: the role of somatic genetic events and the challenges for targeted therapies.

Authors:  Gerald Batist; Jian Hui Wu; Alan Spatz; Wilson H Miller; Eftihia Cocolakis; Caroline Rousseau; Zuanel Diaz; Cristiano Ferrario; Mark Basik
Journal:  Front Pharmacol       Date:  2011-10-05       Impact factor: 5.810

10.  The three dimensional Quantitative Structure Activity Relationships (3D-QSAR) and docking studies of curcumin derivatives as androgen receptor antagonists.

Authors:  Guanhong Xu; Yanyan Chu; Nan Jiang; Jing Yang; Fei Li
Journal:  Int J Mol Sci       Date:  2012-05-18       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.